385 related articles for article (PubMed ID: 34407475)
21. The enhanced antitumor-specific immune response with mannose- and CpG-ODN-coated liposomes delivering TRP2 peptide.
Lai C; Duan S; Ye F; Hou X; Li X; Zhao J; Yu X; Hu Z; Tang Z; Mo F; Yang X; Lu X
Theranostics; 2018; 8(6):1723-1739. PubMed ID: 29556352
[TBL] [Abstract][Full Text] [Related]
22. Programming Injectable DNA Hydrogels Yields Tumor Microenvironment-Activatable and Immune-Instructive Depots for Augmented Chemo-Immunotherapy.
Fan Y; Zhan M; Liang J; Yang X; Zhang B; Shi X; Hu Y
Adv Sci (Weinh); 2023 Oct; 10(29):e2302119. PubMed ID: 37541435
[TBL] [Abstract][Full Text] [Related]
23. External cold atmospheric plasma-responsive on-site hydrogel for remodeling tumor immune microenvironment.
Byun J; Wu Y; Lee J; Kim JS; Shim G; Oh YK
Biomaterials; 2023 Aug; 299():122162. PubMed ID: 37257401
[TBL] [Abstract][Full Text] [Related]
24. Mannosylated engineered trichosanthin-legumain protein vaccine hydrogel for breast cancer immunotherapy.
Chen G; Xiong W; Gu Z; Gao Y; Hou J; Long L; Wang H; Asrorov AM; Muhitdinov B; Xu Q; Huang Y
Int J Biol Macromol; 2022 Dec; 223(Pt A):1485-1494. PubMed ID: 36395942
[TBL] [Abstract][Full Text] [Related]
25. Hollow Aluminum Hydroxide Modified Silica Nanoadjuvants with Amplified Immunotherapy Effects through Immunogenic Cell Death Induction and Antigen Release.
Tan J; Ding B; Zheng P; Chen H; Ma P; Lin J
Small; 2022 Aug; 18(34):e2202462. PubMed ID: 35896867
[TBL] [Abstract][Full Text] [Related]
26. A programmable releasing versatile hydrogel platform boosts systemic immune responses via sculpting tumor immunogenicity and reversing tolerogenic dendritic cells.
Fu W; Li X; Li Y; Luo R; Ou C; Huang D; Liang X; You Y; Wu Q; Gong C
Biomaterials; 2024 Mar; 305():122444. PubMed ID: 38142471
[TBL] [Abstract][Full Text] [Related]
27. Antigen-Loaded Upconversion Nanoparticles for Dendritic Cell Stimulation, Tracking, and Vaccination in Dendritic Cell-Based Immunotherapy.
Xiang J; Xu L; Gong H; Zhu W; Wang C; Xu J; Feng L; Cheng L; Peng R; Liu Z
ACS Nano; 2015 Jun; 9(6):6401-11. PubMed ID: 26028363
[TBL] [Abstract][Full Text] [Related]
28. Tumor lysate-loaded Bacterial Ghosts as a tool for optimized production of therapeutic dendritic cell-based cancer vaccines.
Dobrovolskienė N; Pašukonienė V; Darinskas A; Kraśko JA; Žilionytė K; Mlynska A; Gudlevičienė Ž; Mišeikytė-Kaubrienė E; Schijns V; Lubitz W; Kudela P; Strioga M
Vaccine; 2018 Jul; 36(29):4171-4180. PubMed ID: 29895501
[TBL] [Abstract][Full Text] [Related]
29. A cell-laden hydrogel as prophylactic vaccine and anti-PD-L1 amplifier against autologous tumors.
Li J; Yan Y; Zhang P; Ding J; Huang Y; Jin Y; Li L
J Control Release; 2022 Nov; 351():231-244. PubMed ID: 36122899
[TBL] [Abstract][Full Text] [Related]
30. Co-delivery of anionic epitope/CpG vaccine and IDO inhibitor by self-assembled cationic liposomes for combination melanoma immunotherapy.
Su Q; Wang C; Song H; Zhang C; Liu J; Huang P; Zhang Y; Zhang J; Wang W
J Mater Chem B; 2021 May; 9(18):3892-3899. PubMed ID: 33928989
[TBL] [Abstract][Full Text] [Related]
31. Dendritic cell biology and its role in tumor immunotherapy.
Wang Y; Xiang Y; Xin VW; Wang XW; Peng XC; Liu XQ; Wang D; Li N; Cheng JT; Lyv YN; Cui SZ; Ma Z; Zhang Q; Xin HW
J Hematol Oncol; 2020 Aug; 13(1):107. PubMed ID: 32746880
[TBL] [Abstract][Full Text] [Related]
32. Endogenous/Exogenous Nanovaccines Synergistically Enhance Dendritic Cell-Mediated Tumor Immunotherapy.
Zhang Y; Li Q; Ding M; Xiu W; Shan J; Yuwen L; Yang D; Song X; Yang G; Su X; Mou Y; Teng Z; Dong H
Adv Healthc Mater; 2023 Jul; 12(17):e2203028. PubMed ID: 36807733
[TBL] [Abstract][Full Text] [Related]
33. Fusion of CpG-ODN-stimulating dendritic cells with Lewis lung cancer cells can enhance anti-tumor immune responses.
Du YC; Lin P; Zhang J; Lu YR; Ning QZ; Wang Q
Tissue Antigens; 2006 May; 67(5):368-76. PubMed ID: 16671943
[TBL] [Abstract][Full Text] [Related]
34. Nanomedicines for an Enhanced Immunogenic Cell Death-Based
Zhao C; Wang C; Shan W; Wang Z; Chen X; Deng H
Acc Chem Res; 2024 Mar; 57(6):905-918. PubMed ID: 38417027
[TBL] [Abstract][Full Text] [Related]
35. Acid-Ionizable Iron Nanoadjuvant Augments STING Activation for Personalized Vaccination Immunotherapy of Cancer.
Chen F; Li T; Zhang H; Saeed M; Liu X; Huang L; Wang X; Gao J; Hou B; Lai Y; Ding C; Xu Z; Xie Z; Luo M; Yu H
Adv Mater; 2023 Mar; 35(10):e2209910. PubMed ID: 36576344
[TBL] [Abstract][Full Text] [Related]
36. A therapeutic DC vaccine with maintained immunological activity exhibits robust anti-tumor efficacy.
Lu Y; Shi Y; Liu Y; Luo Z; Zhang J; Jiang M; Li X; Liu X; Guo X; Qin B; Yin H; Du Y; Qiu Y; Lou Y; Guan G; Luo L; You J
J Control Release; 2022 Sep; 349():254-268. PubMed ID: 35803328
[TBL] [Abstract][Full Text] [Related]
37. Dendritic cell gene therapy.
Onaitis M; Kalady MF; Pruitt S; Tyler DS
Surg Oncol Clin N Am; 2002 Jul; 11(3):645-60. PubMed ID: 12487060
[TBL] [Abstract][Full Text] [Related]
38. Immunotheranostic microbubbles (iMBs) - a modular platform for dendritic cell vaccine delivery applied to breast cancer immunotherapy.
Jugniot N; Dahl JJ; Paulmurugan R
J Exp Clin Cancer Res; 2022 Oct; 41(1):299. PubMed ID: 36224614
[TBL] [Abstract][Full Text] [Related]
39. Antigenicity and adjuvanticity co-reinforced personalized cell vaccines based on self-adjuvanted hydrogel for post-surgical cancer vaccination.
He T; Shi Y; Kou X; Shen M; Liang X; Li X; Wu R; You Y; Wu Q; Gong C
Biomaterials; 2023 Oct; 301():122218. PubMed ID: 37393695
[TBL] [Abstract][Full Text] [Related]
40. Blood Clot Scaffold Loaded with Liposome Vaccine and siRNAs Targeting PD-L1 and TIM-3 for Effective DC Activation and Cancer Immunotherapy.
Chen Y; Zhang Y; Wang B; Fan Q; Yang Q; Xu J; Dai H; Xu F; Wang C
ACS Nano; 2023 Jan; 17(1):760-774. PubMed ID: 36520665
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
